CHEMBIO DIAGNOSTICS, INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2022-11-04: Form 8-K; Period of report 2022-11-03; Description 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; Details 2.02.
- 2022-10-04: Form 8-K; Period of report 2022-10-04; Description 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; Details 3.01.
- 2022-09-07: Form 8-K; Period of report 2022-09-07; Description 8.01 Other Events; Details 8.01.
- 2022-08-04: Form 8-K; Period of report 2022-08-04; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2022-11-04 | 8-K | 2022-11-03 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure | 2.02 On November 3, 2022, we issued a press release announcing financial results for the quarter ended September 30, 2022. 7.01 We held an investor conference call on November 3, 2022. | brhc10043738_8k.htm |
| 2022-10-04 | 8-K | 2022-10-04 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 As previously disclosed, on April 5, 2022, Chembio Diagnostics, Inc. (the “Company”) received notification from the Listing Qualifications Department of The Nasdaq Stock Market, or Nasdaq, stating that the Company did not comply with the minimum $1.00 bid price requirement for continued listing set forth in Nasdaq Listing Rule 5550(a)(2) (the “Listing Rule”). | ny20005230x5_8k.htm |
| 2022-09-07 | 8-K | 2022-09-07 | 8.01 Other Events | 8.01 On September 7, 2022, we filed with the Securities and Exchange Commission a registration statement on Form S‑1, or the Registration Statement, relating to a proposed public offering of our common stock, par value $0.01 per share, and pre-funded warrants to purchase shares of common stock, in each case together with warrants to purchase shares of common stock. | ny20005230x2_8k.htm |
| 2022-08-04 | 8-K | 2022-08-04 | 2.02 Results of Operations and Financial Condition | 2.02 On August 4, 2022, we issued a press release announcing financial results for the quarter ended June 30, 2022. | brhc10040239_8k.htm |
| 2022-05-26 | 8-K | 2022-05-24 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 We held our 2022 Annual Meeting of Stockholders on May 24, 2022. | brhc10038206_8k.htm |
| 2022-05-05 | 8-K | 2022-05-05 | 2.02 Results of Operations and Financial Condition | 2.02 On May 5, 2022, we issued a press release announcing financial results for the quarter ended March 31, 2022. | brhc10037250_8k.htm |
| 2022-04-07 | 8-K | 2022-04-05 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 On April 5, 2022, we received a deficiency letter from the Listing Qualifications Department of The Nasdaq Stock Market, or Nasdaq, notifying us that, for the last thirty consecutive business days, the bid price for shares of our common stock had closed below the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2), which we refer to as the Bid Price Requirement. | brhc10036203_8k.htm |
| 2022-03-03 | 8-K | 2022-03-03 | 2.02 Results of Operations and Financial Condition | 2.02 On March 3, 2022, we issued a press release announcing financial results for the quarter and fiscal year ended December 31, 2021. | brhc10034728_8k.htm |
| 2022-02-14 | 8-K | 2022-02-09 | 1.01 Entry into a Material Definitive Agreement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 1.01 On February 9, 2022, we entered into an amendment of our existing employment agreement with Richard L. Eberly, our President and Chief Executive Officer. 5.02 On February 9, 2022, we entered into an amendment of our existing employment agreement with Richard L. Eberly, our President and Chief Executive Officer. | brhc10033944_8k.htm |
| 2022-01-06 | 8-K | 2021-12-30 | 1.01 Entry into a Material Definitive Agreement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 5.02 We entered into an employment agreement dated December 30, 2021 with Lawrence J. Steenvoorden with respect to terms of his employment as our Chief Financial Officer and Executive Vice President, effective as of January 5, 2022. 8.01 On January 5, 2022, we issued a press release entitled “Chembio Diagnostics Announces Appointment of Larry Steenvoorden as Chief Financial Officer,” a copy of which is included as Exhibit 99.1 to this report. | brhc10032547_8k.htm |